Psychotic symptoms occur in B40% of subjects with Alzheimer's disease (AD) and are associated with more rapid cognitive decline and increased functional deficits. They show heritability up to 61% and have been proposed as a marker for a disease subtype suitable for gene mapping efforts. We undertook a combined analysis of three genome-wide association studies (GWASs) to identify loci that (1) increase susceptibility to an AD and subsequent psychotic symptoms; or (2) modify risk of psychotic symptoms in the presence of neurodegeneration caused by AD. In all, 1299 AD cases with psychosis (AD þ P), 735 AD cases without psychosis (AD-P) and 5659 controls were drawn from Genetic and Environmental Risk in AD Consortium 1 (GERAD1), the National Institute on Aging Late-Onset Alzheimer's Disease (NIA-LOAD) family study and the University of Pittsburgh Alzheimer Disease Research Center (ADRC) GWASs. Unobserved genotypes were imputed to provide data on > 1.8 million single-nucleotide polymorphisms (SNPs). Analyses in each data set were completed comparing (1) AD þ P to AD-P cases, and (2) AD þ P cases with controls (GERAD1, ADRC only). Aside from the apolipoprotein E (APOE) locus, the strongest evidence for association was observed in an intergenic region on chromosome 4 (rs753129; 'AD þ PvAD-P' P = 2.85 Â 10
Introduction
Alzheimer's disease (AD), the most common form of dementia, is highly heritable (heritability of up to 76%) but genetically complex. 1 Neuropathologically, the disease is characterized by extracellular senile plaques containing b-amyloid (Ab) and intracellular neurofibrillary tangles containing hyperphosphorylated tau protein. 1 Before 2009, four genes had been definitively implicated in its aetiology. Mutations of the amyloid precursor protein (APP) gene and the presenilin 1 and 2 genes (PSEN1, PSEN2) cause rare, Mendelian forms of the disease usually with an early onset. Until recently, only apolipoprotein E (APOE) had been established unequivocally as a susceptibility gene for the common late-onset form of AD. 1 In 2009, we published a genome-wide association study (GWAS) of AD using the Genetic and Environmental Risk in AD Consortium 1 (GERAD1) sample, 2 which identified two genome-wide significant susceptibility loci: CLU (P = 8.5 Â 10 À10 ) and PICALM (P = 1.3 Â 10
À9
). A second independent AD GWAS performed using the European Alzheimer's Disease Initiative sample (EADI) showed genome-wide significant evidence for association with CLU (P = 7.5 Â 10
) and CR1 (P = 3.7 Â 10 À9 ), and support for PICALM (P = 3 Â 10
À3
). The associations in CLU, PICALM and CR1 have been replicated in several independent data sets [3] [4] [5] [6] and shown relationships with neurodegenerative processes underlying disease. 7 In addition, Seshadri et al. 8 reported genomewide significant association for BIN1 (P = 1.6 Â 10 À11 ) when combining GERAD1 and EADI data with data from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE).
More recently, members of this consortium have reported findings from an extended study by GERAD (GERAD þ ), which included 19 870 AD cases and 39 846 controls and identified genome-wide evidence for association at the ABCA7 locus (P = 5.0 Â 10 À21 ) and the MS4A gene cluster (P = 1.2 Â 10 À16 ). 9 The American Alzheimer's Disease Genetic Consortium (ADGC) also reported genome-wide significant evidence at the MS4A gene cluster, further support for ABCA7 and suggestive evidence for association with single-nucleotide polymorphisms (SNPs) at the CD33, CD2AP, ARID5B and EPHA1 loci. 10 When combining data from ADGC and GERAD þ , SNPs at CD33 (P = 1.6 Â 10 À9 ), CD2AP (P = 8.6 Â 10
À9
) and EPHA1 (P = 6.0 Â 10
À10
) also exceed criteria for genome-wide significant association with AD.
Despite the success of first-generation genome-wide association studies, a substantial proportion of the heritability for complex diseases remains unexplained. 11 It is becoming increasingly apparent that within diagnostic categories, such as bipolar disorder and schizophrenia, extensive aetiological and genetic heterogeneity operates. 12 As a result, there is increasing emphasis on the use of sub-phenotypes to elucidate genotype-phenotype relationships. Psychotic symptoms have been proposed as a marker for a subtype of AD suitable for gene mapping efforts. 13 Psychotic symptoms are significantly more common in AD than the general population, affecting B40% of cases.
14 They are associated with decreased quality of life for caregivers and patients, 15 more rapid cognitive 16 and functional decline 17 and premature institutionalization. 15 We have previously demonstrated familial aggregation of psychosis in AD in three independent cohorts, and estimate that the heritability of AD þ P is B61%. [18] [19] [20] [21] Candidate genes for other psychiatric disorders in nondemented populations have been investigated in relation to AD cases with psychosis (AD þ P), implicating alterations in the serotonergic, dopaminergic, catecholaminergic and noradrenaline neurotransmission systems. 22 However, these findings have not been consistently replicated.
Two possible genetic models of AD þ P are a heterogeneity model in which alleles predispose to the development of AD pathology and subsequent psychosis and a disease modifier model in which they modify risk of psychotic symptoms in the presence of neurodegeneration caused by AD. 22 The current study, the first GWAS of AD þ P, evaluated these two models by contrasting AD þ P with (1) healthy controls (heterogeneity model) and (2) AD cases without psychosis (AD-P; disease modifier model), utilizing existing GWAS data from three independent samples: GERAD1, 2 the National Institute on Aging Late-Onset Alzheimer's Disease Family Study (NIA-LOAD) 21, 23 and the University of Pittsburgh Alzheimer Disease Research Center (ADRC). 24 
Materials and methods

Sample ascertainment
This study included samples from the GERAD1, 2 the NIA-LOAD study 23 and the University of Pittsburgh ADRC 24 GWAS data sets. The GERAD1 sample 1 comprised 543 AD þ P cases, 454 AD-P cases and 4701 controls. All AD cases and 955 controls were genotyped at the Sanger Institute on the Illumina 610-quad chip (Illumina, San Diego, CA, USA). These data were combined with 3746 unscreened population controls from the 1958 British Birth Cohort (1958 BC; http://www.b58cgene.sgul. ac.uk) and UK Blood Service control group genotyped using either the Illumina HumanHap550 BeadChip (n = 2683) or the Illumina HumanOmni1-Quad (n = 1063). All AD cases met criteria for either probable (NINCDS-ADRDA, 25 DSM-IV) or definite (CERAD 26 ) AD. All elderly controls were screened for dementia using the Mini-Mental State Examination (MMSE) or Alzheimer's Disease Assessment Scale-cognitive part (ADAS-cog) or were determined to be free from dementia at neuropathological examination. All individuals in the GERAD sample were of Caucasian ancestry.
Recruitment for the NIA-LOAD cohort has been described previously. 21, 27 In brief, 18 AD centres throughout the United States, each of which had received approval by their institutional review board, participated. The recruitment criteria included a family with multiple members affected with lateonset AD who could provide clinical information and a biological sample for DNA extraction. The current report drew from among all such subjects those who had been previously genotyped by the Center for Inherited Disease Research using the Illumina 610-quad chip (Illumina). The minimum genotype completion rate for any sample released by CIDR was 98.3%. Blind duplicate reproducibility was 99.99% based on 118 paired samples. 23 A total of 260 AD þ P and 125 AD-P subjects from 264 families were analysed. Those in the NIA sample were predominantly of Caucasian ancestry (96.1%), but also included 12 (3.1%) individuals classified as African American and 2 (0.5%) individuals of Native American descent.
University of Pittsburgh ADRC subjects were recruited from the University of Pittsburgh AD Research Center, where all subjects underwent a standard assessment 28 and received diagnoses of possible or probable AD with age of onset X60 years. Autopsy confirmation rates in similarly diagnosed subjects at this centre are > 90%. 29 A total of 496 AD þ P, 156 AD-P subjects and 958 age-matched screened controls of Caucasian ancestry were included. All AD cases met criteria for either probable (NINCDS-ADRDA, 25 DSM-IV) or definite (CERAD 26 ) AD. Control subjects included volunteers at the University of Pittsburgh ADRC who underwent the same assessment and were found to be cognitively normal and also population-based controls who were found to be cognitively normal using a previously described neuropsychological screening battery, 30 which included the MMSE and several additional tests tapping cognitive domains known to be affected in dementia. Genotyping for Pittsburgh subjects was performed using the Illumina Omni1-Quad chip (containing probes for 1.13 million SNPs).
Characterization of psychotic symptoms
The Neuropsychiatric Inventory (NPI) 31 was used to assess behavioural symptoms in all GERAD cases. The NPI is an established and commonly used informant-based rating scale that evaluates 12 common behavioural symptoms in AD. 32 The severity and frequency of each symptom are rated from 0 to 3 and from 0 to 4, respectively, and were scored to reflect the worst episode of each symptom over the lifetime of the illness. Frequency and severity scores are multiplied to give an overall domain score for each symptom ranging from 0 to 12. A total of 42% of the GERAD sample were assessed annually for X2 assessments. Where multiple NPI ratings were available, the highest delusion and hallucination domain scores were used. AD þ P was defined as either the presence of delusions and hallucinations, or where only one symptom was present a delusion domain score of X4 or a hallucination domain score of X2. A more stringent cutoff for delusions was adopted to avoid phenocopy due to transient confabulations. 13 AD cases with delusion and hallucination domain scores of 0 were coded as 'Alzheimer's with no psychosis'. Individuals with intermediate scores were excluded from analysis.
ADRC and NIA-LOAD subjects were rated for psychotic symptoms on the informant-based CERAD behavioural rating scale (CBRS). 33 On more than one occasion, 69 and 35% of the ADRC and NIA-LOAD samples were assessed. A delusion was defined as a false belief based on incorrect inference about external reality, resistant to persuasion or contrary evidence, and not attributable to social or cultural mores. Hallucinations were defined as sensory perceptions for which there was no basis in reality. Discrete hypnagogic and hypnopompic hallucinations, as well as symptoms occurring only during episodes of delirium, were not rated. The CBRS was administered at initial and annual visits and in some subjects between annual visits by telephone. 21, 34 AD þ P was considered present when any of the CBRS items (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) were rated as occurring X3 times in the past month at any visit. Individuals with scores of 0 on the same CBRS items at all visits were classified as AD-P. Inter-rater reliability of the psychosis assessments used, including telephone assessments, has been previously described for the ADRC 22 and NIA-LOAD 21 cohorts. Psychotic symptoms typically emerge in the moderate stages of AD; 21, 35 therefore, those categorized as AD-P who were in the mild stages of disease at their last assessment (Global Deterioration Scale 36 score of < 4, Clinical Dementia Rating 37 score of < 1 or MMSE score 38 of X20) were considered to be at substantial risk of going on to develop delusional or hallucinatory behaviour. These individuals were therefore excluded from the analysis. Hence, a total of 219, 5 and 32 individuals were excluded from the GERAD, NIA-LOAD and ADRC samples, respectively. Subjects with a known history of mood disorders, bipolar disease, unipolar disease or an anxiety disorder were also excluded from all analyses.
Quality control
Quality control (QC) of the GERAD1 sample has been described in detail elsewhere. 2 Briefly, individuals were retained if they had missing genotype rates of < 0.01, with mean autosomal heterozygosity between 0.33 and 0.34, and mean X-chromosome heterozygosity of either < 0.02 for males or between 0.25 and 0.40 for females. Genetic outliers and those showing evidence of relatedness (identity-by-descent estimate X0.125) or non-European ancestry based on genotype data were also excluded. Following QC, 543 AD þ P cases, 454 AD-P cases and 4701 controls were retained. Markers were excluded if they had a minor allele frequency (MAF) of < 0.01 or a Hardy-Weinberg Pp1 Â 10
À5
. SNPs with a MAF of X0.05 were excluded if they had a genotype missing rate of > 0.03; for SNPs with a MAF between 0.01 and 0.05, a more stringent genotype missing rate threshold of 0.01 was employed.
Individuals in the NIA-LOAD sample were retained if they had a missing genotype rate of < 0.05. A total of 260 AD þ P and 125 AD-P subjects falling in 264 families passed QC. Markers were excluded if they had a MAF of < 0.05 or if they had a genotype missing rate of > 0.02. No modifications were made for Hardy-Weinberg equilibrium given the small sample size. A total of 516 835 SNPs passed QC.
QC and analysis of the ADRC sample has been described in detail elsewhere. 39 Briefly, individuals were retained if they had a missing genotype rate of < 0.02, with mean X-chromosome heterozygosity either < 0.02 for males or between 0.25 and 0.4 for females. Genetic outliers and those showing evidence of relatedness (identity-by-descent estimate X0.4) or non-European ancestry based on genotype data were excluded. Following QC, 496 AD þ P cases, 156 AD-P cases and 958 unaffected controls were retained. Markers were excluded if they had a MAF of < 0.01 or a Hardy-Weinberg Pp1 Â 10 À6 in controls. SNPs were also excluded if they had a genotype missing rate of > 0.02. Markers were examined to determine if the rate of missing data was found to depend on case/control status or the genotyping batch. No additional exclusions were needed based on these analyses.
Following QC, this study comprised a total of 1299 cases with AD þ P, 735 individuals characterized as AD-P and 5659 controls.
Imputation
As there is only moderate overlap between the Illumina 550/610 arrays (used in the GERAD1 and NIA-LOAD GWAS) and the Illumina Omni1-Quad array (used in the ADRC GWAS), unobserved genotypes were imputed. The GERAD genotype data were imputed with MACH v.1.0, using haplotypes released from initial low-coverage sequencing of 112 European ancestry samples in the 1000 genomes project (https://mathgen.stats.ox.ac.uk/impute/data_download_ 1000G_pilot_plus_hapmap3.html) as a reference sample. The phasing step included 200 individuals to calculate the specific maps based upon the sample recombination rates. Imputation generated data for > 8.2 million SNPs. On the investigation of several QQ plots from an explorative association analysis, an a posteriori filter was applied to exclude SNPs with MAF < 0.01 or r 2 < 0.3. The ADRC data were also imputed with MACH v.1.0, using haplotypes from the HapMap v3 data release as a reference sample. Imputation generated data for > 3 million SNPs that were subsequently filtered to exclude SNPs with r 2 < 0.3. Imputed genotypes were not available for the NIA-LOAD data set.
Association analyses GERAD1. Separate analyses were completed to compare AD þ P with unaffected controls and AD-P cases. Following QC, 4 659 431 and 4 479 280 SNPs were tested in the 'AD þ PvControl' and 'AD þ PvAD-P' analyses, respectively. Analyses were completed using logistic regression assuming an additive model. The first four principal components extracted from an EIGENSTRAT 40 analysis were included as covariates.
ADRC. Separate analyses were performed to compare AD þ P with unaffected controls and AD-P cases in the ADRC sample. Following imputation and QC, a total of 2 543 888 SNPs were tested in each analysis. Analyses were performed using logistic regression assuming an additive model in PLINK. 41 Age (age at exam for unaffected controls or age at diagnosis for AD cases), sex and the first four principal components extracted from a multidimensional scaling analysis (also implemented in PLINK) were included as covariates in the analyses.
NIA-LOAD.
The NIA-LOAD sample included AD cases sampled from multiplex families. As some of the subjects were related, the contrast of AD þ P versus AD-P was performed using generalized estimating equation methods. For simplicity, we assumed all relative pairs were related as full siblings, a conservative assumption, and accounted for their estimated covariance in tests contrasting AD þ P versus AD-P allele frequencies. To account for differences in genetic ancestry, cases and controls were matched based on genetic distances calculated from the eight significant dimensions of ancestry as determined by SpectralGem. 42 
Meta-analyses
An inverse variance weighted fixed effects metaanalysis was used to test for association with AD þ P in the GERAD1, NIA-LOAD and ADRC data sets. Separate meta-analyses were completed for 'ADPvControls' (including summary statistics from GER-AD1 and ADRC) and 'AD þ PvAD-P' (including summary statistics from GERAD1, NIA-LOAD and ADRC). Cochran's Q-test was performed and I 2 calculated to assess heterogeneity. SNPs present, and passing all QC filters, in X2 studies were included. All analyses were completed using METAL (http://www.sph.umich.edu/csg/abecasis/metal/). 43 
Results
A total of 1299 AD þ P cases, 735 AD-P cases and 5659 controls were included in the meta-analysis. Clinical characteristics of the sample are presented in Table 1 . The final meta-analysis of the 'AD þ PvControl' and 'AD þ PvAD-P' data sets included 1 847 262 and 1 882 172 SNPs, respectively. The genomic control inflation factors (l) 44 were 1.002 and 1.004, respectively, suggesting little evidence for residual stratification. Table 2 shows loci associated (P < 1.0 Â 10 À5 ) with AD þ P when compared with either controls or AD-P cases. Summary statistics for SNPs with P-values p1 Â 10 À4 can be found for 'AD þ Pvcontrols' and 'AD þ PvAD-P analyses in Supplementary Tables 1 and 2 , respectively. Figure 1 includes Manhattan plots of the 'ADPvControls' and 'AD þ PvAD-P' GWAS. Excluding the APOE region, the most significant SNP (rs753129) had a P-value of 2.85 Â 10 À7 (odds ratio (OR) = 0.66) and was associated with AD þ P when compared with AD-P cases. rs753129 is in an intergenic region on chromosome 4. The same SNP showed some evidence for association in analysis of 'AD þ PvControls' (OR = 0.81, P = 1.11 Â 10
À4
). The most significant SNP outside the APOE locus in the 'AD þ PvControl' analysis was rs6834555, which sits just upstream of the solute carrier family 2 (facilitated glucose transporter), member 9 (SLC2A9) gene (OR = 1.39, P = 3.0 Â 10
À7
). This SNP was not associated with AD þ P when compared with AD-P (OR = 1.13, P = 0.18). The most significant intragenic SNP in the 'AD þ PvControl' analysis was rs4038131, an intronic SNP in the visinin-like 1 (VSNL1) gene (OR = 0.65, P = 5.9 Â 10
). This SNP was also associated with AD þ P when compared with AD-P cases (OR = 0.72, P = 1.84 Â 10
À2
). No evidence of association was observed at the APOE locus when analysing 'AD þ PvAD-P' (all P > 0.235). Six SNPs in close proximity to APOE showed genome-wide significant associations when comparing AD þ P cases with controls. All of these markers showed similar patterns of effect and more compelling evidence of association in the primary analysis of the GERAD þ stage 1 analysis, which did not condition on presence or absence of psychotic symptoms (P-values ranging from 3.5 Â 10 À39 to 1.6 Â 10
À215
). 9 Furthermore, none of these SNPs showed evidence of association with AD þ P when compared with AD-P (P > 0.330), indicating that the APOE locus is associated with AD, unconditional of psychosis status. Results for these SNPs at the APOE locus can be found in Supplementary Table 3 .
Recent GWAS studies of AD have identified compelling evidence for nine novel risk loci for AD: CLU, PICALM, CR1, BIN1, ABCA7, MS4A, CD2AP, CD33 and EPHA1. 2, [8] [9] [10] 45 In this study, comprising a subset of the GERAD, 9 NIA-LOAD 10 and University of Pittsburgh ADRC 24 samples included in the studies that identified these loci, we noted association (P < 0.05) with BIN1 (rs744373, P = 2.6 Â 1
À5
, OR = 0.80), EPHA1 (rs11767557, P = 0.002, OR = 1.22), CLU (rs11136000, P = 0.005, OR 0.86), MS4A (rs670139, P = 0.028, OR = 1.12) and PICALM (rs3851179, P = 7.2 Â 10
, OR = 0.81) when comparing AD þ P cases with controls. The pattern of effect was consistent with that observed in the primary analysis of the GERAD þ data set and none of these SNPs showed evidence of association when comparing AD þ P and AD-P cases, suggesting that these loci are associated with AD, irrespective of the presence or absence of psychotic symptoms (see Supplementary  Table 4) .
Finally, we investigated whether putative risk loci for schizophrenia or bipolar disorder, both of which feature prominent psychotic symptoms, were asso- ciated with AD þ P when compared with AD-P or controls (Table 3) . We tested those SNPs that have shown genome-wide significant evidence for association (Pp5.0 Â 10 À8 ) in GWAS of schizophrenia or bipolar disorder. In all, 11 SNPs were chosen, 6 of which were identified by GWAS of schizophrenia 46, 47, 51 and 5 by GWAS of bipolar disorder. [48] [49] [50] Although individually, GWA SNPs showed only limited association with AD þ PvAD-P, as a group there was a trend toward association, combined P = 0.109 (using an unweighted Z-transformation, 52 excluding rs1938526 and rs13194053 as they are in strong linkage disequilibrium with rs10994336 and rs6932590, respectively) We also identified 5 additional loci without genome-wide significant evidence for association in schizophrenia or bipolar disorder, but implicated by meta-analysis as listed in the top 10 schizophreniaGene loci on 1 June 2011 (http:// www.szgene.org/). These SNPs showed no evidence of association with AD þ PvAD-P individually, or as a group (combined P = 0.90; see Table 3 ).
Discussion
A substantial body of evidence indicates that the presence of psychotic symptoms in AD identifies a subgroup of subjects who undergo more rapid cognitive and functional decline. 22 The distinctive nature of the AD þ P phenotype, in conjunction with evidence of the familial aggregation and heritability of psychosis in AD, has led to the hypothesis that AD þ P may have a genetic architecture that diverges from that of AD-P. 13 There are two plausible genetic models of AD þ P. First, a heterogeneity model in which alleles predispose to the development of AD pathology and subsequent psychosis and, second, a disease modifier model in which alleles increase the risk of psychosis conditioned on the presence of AD. 22 The current study evaluated these two models by contrasting AD þ P with healthy controls and with AD-P subjects.
Although we did not observe novel genome-wide significant evidence of association with AD þ P when compared with healthy controls or AD-P cases, several additional considerations apply. Despite testing for association in one of the largest cohorts of AD þ P and AD-P subjects studied to date, the power of the present study to detect loci of the magnitude commonly observed in complex traits is limited. For example, for common variants (MAF = 0.3), the current study has 0.02 and 0.06 power to detect disease susceptibility loci with OR of 1.2 in the À8 were observed. All of these markers showed similar patterns of effect and more compelling evidence of association in the primary analysis of the GERAD1 data set, which tested for association with AD, irrespective of psychosis status. 2 Furthermore, none of these SNPs showed evidence of association with AD þ P when compared with AD-P (P > 0.235). These SNPs can be found in Supplementary Table 3. 'AD þ PvAD-P' and 'AD þ PvControl' analyses, respectively, and power is even less for lower frequency alleles that confer this effect size. It is therefore possible that many SNPs in the current study, while failing to reach this stringent level of statistical significance, could reflect true disease loci with resulting implications for the biology of AD þ P. For example, the most significant intragenic SNP in the 'AD þ PvControl' analysis was rs4038131, an intronic SNP in the VSNL1 gene. VSNL1 utilizes a calciummyristoyl switch mechanism that upon stimulation by intracellular calcium causes VSNL1 to translocate to cell membranes, including the transGolgi apparatus, where it may influence a number of cell signalling pathways. 53 VSNL1 concentrations are elevated in the cerebrospinal fluid of individuals with AD, where they correlate with cerebrospinal fluid tau concentrations and with the degree of Figure 1 Scatterplot of chromosomal position (x axis) against Àlog 10 genome-wide association study (GWAS) P-value (y axis). (a) Alzheimer's disease cases with psychosis (AD þ P) versus controls and (b) AD þ P versus Alzheimer's disease cases without psychosis (AD-P). The threshold for genome-wide significance (Pp9.5 Â 10
À8
) is indicated by the red horizontal line. The y axis scale has been limited to 10 (P = 1 Â 10 À10 ), although highly significant association was observed with SNPs in the vicinity of the apolipoprotein E (APOE) locus when comparing AD þ P cases with controls. Plots produced using Haploview v4.0 (http://www.broad.mit.edu/mpg/haploview/). cognitive impairment. 54 Whether VSNL1 expression in cerebral cortex of AD þ P subjects is reduced in comparison with AD-P subjects is not known, but VSNL1 mRNA and protein expression are reduced in cerebral cortex of subjects with schizophrenia. 55, 56 Another SNP that showed suggestive evidence of association when comparing AD þ P cases with controls was rs6834555, which is located just 5 0 of the urate transporter, SLC2A9. Variation in SLC2A9 has been shown to influence serum urate concentrations across populations. 57, 58 Of interest, reduced serum urate concentration has been identified in AD 59 and in schizophrenia. 60, 61 Serum and cerebrospinal fluid urate have also been shown to be positively correlated. 59 How altered urate concentration may relate to the brain pathologies observed in schizophrenia and AD is not known, although the protective antioxidant effects of urate have been suggested as one potential mechanism. [59] [60] [61] Relatively less evidence currently exists to suggest that the SNPs identified in the 'AD þ PvAD-P' analysis may be tied to the neurobiology of AD or psychosis. One exception may be serine/ threonine kinase 11 (STK11). An unusually largescale STK11 deletion has been described in one case in which Peutz-Jeghers syndrome, mental retardation and schizophrenia co-occurred, 62 and reduced copy numbers of STK11 have been reported in affected siblings with schizophrenia. 63 In contrast to the above genes, we found little evidence to suggest that previously identified AD risk genes may contribute selectively to the risk of psychosis within AD. Several of these loci showed association when contrasting AD þ P cases with controls; however, the effect sizes were comparable to those obtained when comparing AD cases unselected for psychotic symptoms with controls. Furthermore, none of these loci showed association in the 'AD þ PvAD-P' analysis. This conclusion should be tempered by awareness of the limited power in our 'AD þ P v AD-P' comparison.
We previously identified 22 studies, comprising more than 5200 subjects with AD, that examined the association of the APOE e4 allele with AD þ P, with 9 reporting significant associations. 22 Although not supportive of a true association of APOE with AD þ P, such a pattern could result from false negatives because of variation between studies in terms of subject populations, sample sizes, definitions of AD þ P and analytic approaches, or because of limited power to detect small, but real effects (for example, O.R 1.1-1.2). A recent examination of the largest sample to date of AD subjects uniformly characterized for psychosis (N = 2317) found that neither APOE e4 carrier status nor allele number was associated with psychosis. 64 Alternatively, the variable pattern of association might reflect causal association with genetic variation in linkage disequilibrium with the APOE e4 allele. The current study, which found no association with AD þ P of SNPs throughout the chromosome 19 region containing APOE, tested in more than 2000 AD cases characterized for psychosis, does not support this alternative. Similarly, when examined in samples that largely overlap with the current ADRC cohort, there was no evidence of association of AD þ P with a poly-T repeat length variation in TOMM40, which is in linkage disequilibrium with APOE. 65 Taken as a whole, these data do not support a role of APOE in the risk for psychosis within AD subjects, a finding consistent with a current meta-analysis of 26 studies that finds no association of APOE e4 alleles with the risk for schizophrenia (www.szgene.org).
These analyses are largely hypothesis generating. It is now important to follow-up these findings, either through replication or meta-analysis of other AD GWAS data sets where psychotic symptoms have been well characterized. Hence, we will make the complete genome-wide meta-analysis results for 'AD þ PvAD-P' and 'AD þ PvControls' available to researchers upon application. It also notable that this study was limited to mainly those of Caucasian origin. Future studies may seek to investigate AD þ P within other ethnic groups. It is interesting to note that some overlap between schizophrenia and psychosis in AD was observed. There is increasing evidence that there is genetic overlap between the major psychiatric 66, 67 and nonpsychiatric 68 disorders. The largest family study of bipolar disorder and schizophrenia has recently been published. It showed that there are increased risks of both schizophrenia and bipolar disorder to first-degree relatives of probands with either disorder, which was largely because of additive genetic effects. 66 Furthermore, a recent study provides strong evidence that schizophrenia is largely polygenic, involving many common SNPs that are substantially shared with bipolar disorder. 67 It is plausible that this overlap will extend to other disease phenotypes with prominent psychotic symptoms. A vital part of dissecting large amounts of GWAS data available in psychiatric and neuropsychiatric populations will be working toward more biologically valid classification approaches, which will allow genetic mappings of symptom domains and dimensions that will undoubtedly lead to greater understanding of clinical phenotypes. 69 It is important to note that there are no established criteria for defining AD þ P. We took several approaches in order to minimize the possibility of misclassification of subjects. Because rates of AD þ P increase with disease progression, we used all available longitudinal structured ratings of behavioural pathology within subjects to identify AD þ P as the occurrence of symptoms at any time point. We excluded individuals with transient mild psychotic symptoms to avoid phenocopies due to misunderstanding of confusional episodes. Similarly, we excluded nonpsychotic individuals in the earliest stages of illness who may have been at risk of expressing psychosis only after their illness progressed. These operationalized criteria for AD þ P map closely to those used in our earlier studies that demonstrated familial aggregation of AD þ P in AD.
18,21 Nevertheless, we cannot rule out the possibility that because the extent of longitudinal data varied for individuals, some individuals may have been misclassified with regard to their psychosis status. It is also notable that there were different proportions of individuals in each sample categorized as AD þ P and AD-P. This likely reflects differences in the availability of longitudinal ratings and disease severity, subtle differences in rating instruments and also differences resulting from the underlying populations studies. By performing analyses in each cohort, controlling for population substructure and combining results through meta-analyses, we limit the effect that these differences will have on the results of this study.
This study also included unscreened, populationbased controls in the AD þ PvControl analysis. Unscreened controls are commonly used in GWAS studies and can substantially increase power to detect true genetic associations where disease prevalence is low (K p < 0.2). 70 It is noteworthy that the GERAD GWAS, which includes a large proportion of unscreened controls, has already produced compelling evidence for new susceptibility genes for AD: CLU, PICALM, BIN1, CR1, ABCA7, MS4A, CD2AP, CD33 and EPHA1. Of these, CLU, PICALM, BIN1, CR1, ABCA7 and MS4A have since been replicated in independent samples. 3, 5, 7, 10, 71, 72 Despite the pragmatic value of unscreened controls, there are potential limitations to their use. Although the population prevalence of AD þ P is low, which largely reflects its age dependency, a high proportion of individuals among unscreened controls may carry genetic risk for AD þ P and would be anticipated to manifest this syndrome if they were evaluated through the age of risk. As such, contrasts between AD þ P and unscreened controls may fail to detect some meaningful genetic associations. Also, because of age differences between AD subjects and unscreened controls, some SNPs associated with AD þ P in the 'ADPvControl' comparison may represent confounds because of a true association with a survival advantage. These potential limitations are mitigated somewhat in the current study by the inclusion of screened elderly controls. Similarly, loci with evidence of association in both the 'AD þ PvControl' and the 'AD þ PvAD-P' (for example, VSNL1) are less likely to result from this confounding.
In conclusion, this study does not identify any SNPs that meet strict criteria for genome-wide significant association with AD þ P when compared with controls or AD-P cases. However, a number of sub-threshold associations were observed that (1) show patterns of effect that are stronger than those generally observed in AD GWAS, (2) are interesting biological and position candidates for AD þ P and (3) show some overlap with other psychiatric disorders with psychotic features. Hence, these findings warrant further investigation in larger, appropriately powered samples in which the presence of psychotic symptoms in AD is well characterized.
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